Boltz Raises $110 Million to Build Its Pharmaceutical AI Business
The Series A, led by Bessemer, will support headcount growth and additional computing infrastructure.

Boltz PBC raised $110 million in a Series A led by Bessemer, giving the pharmaceutical AI startup funding to grow its headcount and add computing infrastructure.
Greycroft, Andreessen Horowitz, Amplify Partners, F-Prime Capital, Hummingbird and other new and returning investors joined the round. Boltz announced the financing Wednesday.
The company develops artificial intelligence models for pharmaceutical researchers. Its BoltzMol-1 model evaluates a smaller set of promising small molecules to generate binding-affinity data, which helps researchers assess how strongly a molecule may bind to a biological target.
Boltz’s BoltzProt-1 model generates protein designs using data from small-molecule hits, then reviews each design for potential use in drug development.